Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer

Oncology Reports

Volumn 7, Issue 4, 2000, Pages 875-877

  Klein, B ^a   Sadikov, E ^a   Mishaeli, M ^a   Levin, I ^a   Figer, A ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b Institute of Oncology   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

5 FU; Gemcitabine; Leukovorin; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034220872     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.4.875     Document Type: Review

References (14)

1. Siverberg E, Boring C and Squiers TS: Cancer statistics 1990. CA 40: 9-26, 1990.
2. Williamson RCN: Pancreatic cancer: the greatest oncological challenge. Br Med J 296: 445-446, 1988.
3. Carter SK: The integration of chemotherapy into a combined modality approach for cancer treatment. IV. Pancreatic adenocarcinoma. Cancer Tret Rev 2: 193-214, 1975.
4. Erlichman C, Fine S, Wong A, et al: A randomized trail of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469-475, 1988.
5. Figer A, Sadikov E, Mishaeli M, Koren R, Gali R, Levin I and Klein B: A comparison of two dose regimens in pancreatic cancer. J Chemother (In press).
6. Heinemann V, Hertel L, Grindey GB, et al: Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluorodeoxycytidine and 1-b-D-arabinofuranosyl cytosine. Cancer Res 48: 4024-4031, 1988.
7. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994.
8. Burris HA, Moore MJ, Anderson J, et al: Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
9. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7: 347-353, 1996.
10. Burris HA: Objective outcome measures of quality of life. Oncology-Huntingt 10(Suppl 11): 131-135, 1996.
11. Kroep JR, Pinedo HM, van Groeningen CJ, et al: Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 10 (Suppl 4): 234-238, 1999.
12. Hidalgo M, Castellano D, Paz-Ares L, et al: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592, 1999.
13. Borner MM, Maurer CA, Friess H, et al: Gemcitabine (GEM) and continuous infusion fluorouracil (CIF): a phase II study in advanced pancreatic cancer (APC). Ann Oncol 9 (Suppl 4): A241P, 1998.
14. Heinemann V, Scherumly NM, Stieber P, et al: Ca-19.9: a predictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 19(4A): 2433-2435, 1999.